Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001950047-25-009968
Filing Date
2025-12-08
Accepted
2025-12-08 18:03:06
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 4047
  Complete submission text file 0001950047-25-009968.txt   5520
Mailing Address BLUEPRINT MEDICINES CORP. 215 FIRST STREET, SUITE 340/350 CAMBRIDGE MA 02142
Business Address
Albers Jeffrey W. (Reporting) CIK: 0001638474 (see all company filings)

Type: 144

Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Subject) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 001-39460 | Film No.: 251557144
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)